WallStreetZenWallStreetZen

NYSE: ABBV
Abbvie Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ABBV

Based on 12 analysts offering 12 month price targets for Abbvie Inc

Min Forecast
$190.00-0.64%
Avg Forecast
$216.00+12.96%
Max Forecast
$250.00+30.74%

Should I buy or sell ABBV stock?

Based on 12 analysts offering ratings for Abbvie Inc.

Buy
Strong Buy
5 analysts 41.67%
Buy
3 analysts 25%
Hold
4 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their ABBV stock forecasts and price targets.

ABBV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-14Find Out Why
lockedlocked$00.00+00.00%2025-04-29Find Out Why
lockedlocked$00.00+00.00%2025-04-28
lockedlocked$00.00+00.00%2025-04-28
lockedlocked$00.00+00.00%2025-04-28Find Out Why
Cantor Fitzgerald
Top 15%
86
Strong BuyInitiates Coverage On$210.00+9.82%2025-04-22
Goldman Sachs
Bottom 46%
46
HoldAssumes$194.00+1.45%2025-04-08
Wells Fargo
Top 17%
84
Strong BuyMaintains$240.00+25.51%2025-03-05
Bank of America
Top 27%
74
HoldMaintains$223.00+16.62%2025-03-04
Truist Securities
Bottom 7%
7
Strong BuyMaintains$217.00+13.48%2025-02-03

1 of 2

Forecast return on equity

Is ABBV forecast to generate an efficient return?

Company
2,115.21%
Industry
353.91%
Market
91.6%
ABBV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ABBV forecast to generate an efficient return on assets?

Company
22.06%
Industry
24.83%
ABBV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ABBV earnings per share forecast

What is ABBV's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$11.96+406.95%
Avg 2 year Forecast
$14.08+496.63%
Avg 3 year Forecast
$15.68+564.26%
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

ABBV revenue forecast

What is ABBV's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$60.2B+4.94%
Avg 2 year Forecast
$65.3B+13.78%
Avg 3 year Forecast
$70.0B+22.09%
ABBV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ABBV earnings growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
88.44%
Industry
35.16%
Market
15.72%
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
ABBV's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

ABBV revenue growth forecast

How is ABBV forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
6.9%
Industry
7.71%
Market
10.62%
ABBV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ABBV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ABBV vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
ABBV$191.22$216.00+12.96%Buy
JNJ$168.11$173.11+2.97%Buy
AZN$73.98N/AN/A
NVS$117.22N/AN/A
MRK$82.63$99.29+20.16%Buy
View Top General Drug Manufacturer Stocks

Abbvie Stock Forecast FAQ

Is Abbvie Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NYSE: ABBV) stock is to Buy ABBV stock.

Out of 12 analysts, 5 (41.67%) are recommending ABBV as a Strong Buy, 3 (25%) are recommending ABBV as a Buy, 4 (33.33%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell.

If you're new to stock investing, here's how to buy Abbvie stock.

What is ABBV's earnings growth forecast for 2025-2027?

(NYSE: ABBV) Abbvie's forecast annual earnings growth rate of 88.44% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 35.16%, and it is also forecast to beat the US market's average forecast earnings growth rate of 15.72%.

Abbvie's earnings in 2025 is $4,195,000,000.On average, 10 Wall Street analysts forecast ABBV's earnings for 2025 to be $21,133,245,815, with the lowest ABBV earnings forecast at $20,861,219,749, and the highest ABBV earnings forecast at $21,991,717,686. On average, 10 Wall Street analysts forecast ABBV's earnings for 2026 to be $24,871,837,822, with the lowest ABBV earnings forecast at $23,811,112,804, and the highest ABBV earnings forecast at $26,655,021,677.

In 2027, ABBV is forecast to generate $27,691,193,693 in earnings, with the lowest earnings forecast at $26,301,741,072 and the highest earnings forecast at $30,329,139,974.

What is ABBV's revenue growth forecast for 2025-2027?

(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 6.9% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.62%.

Abbvie's revenue in 2025 is $57,367,000,000.On average, 7 Wall Street analysts forecast ABBV's revenue for 2025 to be $106,338,654,547,443, with the lowest ABBV revenue forecast at $105,500,187,190,602, and the highest ABBV revenue forecast at $108,219,250,230,930. On average, 7 Wall Street analysts forecast ABBV's revenue for 2026 to be $115,300,662,814,006, with the lowest ABBV revenue forecast at $112,367,962,159,578, and the highest ABBV revenue forecast at $118,935,137,727,031.

In 2027, ABBV is forecast to generate $123,716,015,270,191 in revenue, with the lowest revenue forecast at $119,846,912,575,896 and the highest revenue forecast at $127,590,646,805,961.

What is ABBV's forecast return on assets (ROA) for 2025-2028?

(NYSE: ABBV) forecast ROA is 22.06%, which is lower than the forecast US Drug Manufacturers - General industry average of 24.83%.

What is ABBV's Price Target?

According to 12 Wall Street analysts that have issued a 1 year ABBV price target, the average ABBV price target is $216.00, with the highest ABBV stock price forecast at $250.00 and the lowest ABBV stock price forecast at $190.00.

On average, Wall Street analysts predict that Abbvie's share price could reach $216.00 by May 14, 2026. The average Abbvie stock price prediction forecasts a potential upside of 12.96% from the current ABBV share price of $191.22.

What is ABBV's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: ABBV) Abbvie's current Earnings Per Share (EPS) is $2.36. On average, analysts forecast that ABBV's EPS will be $11.96 for 2025, with the lowest EPS forecast at $11.81, and the highest EPS forecast at $12.45. On average, analysts forecast that ABBV's EPS will be $14.08 for 2026, with the lowest EPS forecast at $13.48, and the highest EPS forecast at $15.09. In 2027, ABBV's EPS is forecast to hit $15.68 (min: $14.89, max: $17.17).

What is ABBV's forecast return on equity (ROE) for 2025-2028?

(NYSE: ABBV) forecast ROE is 2,115.21%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.